Last updated: June 8, 2026
PREMPRO Suppliers: Who Manufactures Premarin + Provera and Its Generic Alternatives?
PREMPRO (conjugated estrogens/medroxyprogesterone acetate) is marketed in the US as a branded, dual-hormone product. Supply for PREMPRO and route-to-market pressure from generics typically centers on (1) the branded product label supply chain and (2) generic ANDA manufacturers of oral fixed-dose tablets using either directly sourced actives or custom synthesis.
Actionable bottom line for sourcing and IP risk: PREMPRO supply is dominated by legacy branded manufacturing and ongoing generic tablet availability. The supplier set is best mapped by (a) FDA Orange Book “Applicant/Manufacturer” listings for the specific strength(s) and (b) the ANDA sponsor + dosage-form for tablet generics. Without the Orange Book strength-level entries, a complete supplier roster cannot be stated accurately.
What companies supply PREMPRO (Premarin plus Provera) tablets in the US?
Which supplier list matters for procurement
For PREMPRO sourcing, the controlling supplier fields are typically:
- FDA Orange Book “Applicant” (ANDA/BLA/brand sponsor credited for regulatory responsibility)
- FDA Orange Book “Manufacturer” (site manufacturing labeled by FDA for the listed product)
- Labeler/distributor on the US package (commercial logistics, not always the manufacturing site)
Why supplier identity varies by strength and NDC
PREMPRO has multiple strengths, and FDA listings can differ by:
- labeler and distributor
- manufacturing site(s)
- generic substitution equivalents at the NDC level
A strength-level and NDC-level mapping is required to build a reliable “who supplies what” roster.
Which FDA Orange Book entries define PREMPRO suppliers for each strength?
How to interpret Orange Book fields
Orange Book records usually provide:
- Active ingredient(s): conjugated estrogens and medroxyprogesterone acetate
- Dosage form: tablet
- Strength: strength-specific
- Applicant/Manufacturer: sponsor and manufacturing label
What to extract for supplier diligence
For each PREMPRO strength, extract:
- NDC(s) associated with the tablet strength
- Orange Book applicant and manufacturer
- Patent and exclusivity status (to understand when supply can shift due to generic approvals)
What generic ANDA manufacturers supply PREMPRO tablets and how do they compete on supply?
Generic supply usually tracks ANDA sponsors
For fixed-dose oral combination products like PREMPRO, generic supply is typically:
- constrained by formulation bioequivalence and stability work
- exposed to manufacturing site capacity for oral tablets
Common competitive pressure points
- tablet cGMP capacity
- API sourcing continuity for conjugated estrogens and medroxyprogesterone acetate
- regulatory changes affecting manufacturing or labeling
A complete manufacturer list requires direct Orange Book/ANDA sponsor extraction by strength.
Do biosimilars apply to PREMPRO, or is the competition strictly generic tablets?
PREMPRO is a small-molecule hormone combination (not a biologic), so:
- biosimilars do not apply
- competition is generic ANDAs for oral tablet strengths
Supply risk and market entry risk therefore map to ANDA availability, site approvals, and generic launch timing, not biologic interchangeability or biosimilar exclusivity.
What are the typical upstream API suppliers for conjugated estrogens and medroxyprogesterone acetate?
Upstream sourcing pattern
For estrogen and progestin actives, common upstream sourcing patterns include:
- contract API manufacturing for steroid intermediates
- multi-source availability for established actives
- quality-system qualification of external suppliers for drug product manufacturers
What is required for a defensible supplier map
A credible “API supplier” list requires:
- drug master file (DMF) holders or referenced suppliers in regulatory filings
- published supplier acknowledgments in labels or regulatory submissions
- site-specific confirmation from batch records or audit reports
Without strength- and site-level regulatory extraction, upstream API supplier naming cannot be completed accurately.
How do licensing and distribution arrangements affect PREMPRO supply (who sells vs who makes)?
Branded product dynamics
Branded hormonal products often have:
- one primary manufacturing site
- distribution through a labeler/distributor network
- possible packaging/secondary processing partners by region
Generic distribution
Generics often have:
- multiple distributors
- fewer manufacturing sites with larger capacity scaling
Procurement should distinguish:
- regulatory manufacturer vs
- commercial distributor to avoid supply-chain surprises.
What manufacturing/IP barriers can disrupt PREMPRO supply for generics?
Tablet combination-specific barriers
Key barriers include:
- maintaining bioequivalence for fixed-dose combinations
- stability of the combination during storage
- consistent dissolution profiles across strengths
IP and exclusivity effects
While supply can widen after approvals, supply continuity can still be impacted by:
- patent thickets around formulation, method of use, or process
- settlement terms that delay certain generic strengths
- FDA exclusivity periods linked to specific ANDA applicants
A full barrier map needs the Orange Book patent and exclusivity timeline by strength.
When do generic entry risks and launch timing matter most for PREMPRO?
Timing mechanics
Generic entry timing depends on:
- patent expiration for listed patents in Orange Book for the exact strength
- exclusivity periods (application-specific exclusivity)
- any patent litigation and settlement triggers
Why this is procurement-relevant
If multiple generics launch at once, supply generally improves. If litigation delays apply to one or more strengths, shortages can persist.
A defensible timing model requires the Orange Book expiry dates and exclusivity blocks for PREMPRO.
Key Takeaways
- PREMPRO is a fixed-dose oral combination tablet, so competition is generic ANDAs, not biosimilars.
- For supplier identification, the controlling datasets are the FDA Orange Book “Applicant” and “Manufacturer” fields by strength plus the associated NDCs.
- Upstream API suppliers (for conjugated estrogens and medroxyprogesterone acetate) cannot be named reliably without regulatory filing-level linkage or site-specific confirmations.
- Generic supply and disruption risk track ANDA sponsor manufacturing capacity and patent/exclusivity status by strength.
FAQs
-
How do I confirm the manufacturer of PREMPRO tablets for a specific NDC?
Use the strength/NDC-specific FDA Orange Book record and match the listed “Manufacturer” to the packaged NDC.
-
Is PREMPRO protected by formulation or method-of-use patents that affect generic supply?
Generic entry depends on the Orange Book-listed patents tied to each strength, which may include formulation or method-of-use claims.
-
What are the main drivers of PREMPRO generic supply stability?
Tablet cGMP capacity, API sourcing continuity for steroid actives, and compliance with bioequivalence/stability requirements.
-
Do settlement agreements change PREMPRO generic launch timing?
Yes, if a Paragraph IV action leads to Hatch-Waxman settlements that delay or block launch for specific strengths.
-
Can multiple manufacturers supply the same PREMPRO strength under different NDCs?
Yes, labeler and manufacturing site can vary by NDC, making NDC-level mapping essential.
References (APA)
- FDA. (n.d.). Drugs@FDA: PREMPRO (conjugated estrogens; medroxyprogesterone acetate). U.S. Food and Drug Administration. https://www.accessdata.fda.gov/scripts/cder/daf/
- FDA. (n.d.). FDA Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations (PREMPRO). U.S. Food and Drug Administration. https://www.accessdata.fda.gov/scripts/cder/ob/
